StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
RAY-B.ST$219.60+0.18%
Fair $219.60+0.0%

RAY-B.ST

RaySearch Laboratories AB (publ)

Healthcare / Health Information ServicesStockholm

$219.60

+0.40 (+0.18%)

Fairly Valued+0.0%Fair Value $219.60Fund rank 37/100 · Data gapFallback financials|
SA 54/C
F-Score: 8/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 23% · confianza 25%

FCF escenarios

weak_data · normalized FCF $246.6M · quality 76.0/100

Data gap 37/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 83/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

54/100

C

Piotroski

8/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · RAY-B.STLocal privado en este navegador · RaySearch Laboratories AB (publ)
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$7.5B

P/E

33.6x

↑

EV/EBITDA

12.8x

↑

ROE

23.1%

↑

Gross Margin

92.4%

↑

Debt/Equity

0.40

↑
52-Week Range$220
$167$374

TradingView lightweight chart

RAY-B.ST price, volumen y niveles de valoración

Último $219.60Periodo +1082.1%
Fair value: $219.60

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+16.8%

FCF CAGR

+10.0%

FCF margin

11.8%

FCF / Net income

0.70x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $1.34B · net income $227.8M · FCF $158.9M

2022-FY → 2025-FY

Gross margin

92.4%+3.7% pts

Operating margin

24.5%+20.9% pts

Net margin

16.9%+14.1% pts

FCF margin

11.8%-2.3% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$1.34B$1.34B$1.19B$1.02B$843.6M
Net Income$227.8M$227.8M$203.5M$81.6M$23.8M
EBITDA$586.8M$586.8M$571.3M$405.9M$340.8M
EPS6.656.655.942.380.69
Gross Margin92.4%92.4%91.7%89.6%88.7%
Operating Margin24.5%24.5%21.1%12.0%3.6%
Net Margin16.9%16.9%17.1%8.0%2.8%
Balance Sheet
Debt/Equity0.400.400.540.720.85
Current Ratio1.791.79———
Cash Flow
Free Cash Flow$158.9M$158.9M$267.6M$246.6M$119.3M
Returns
ROE23.1%23.1%23.2%11.1%3.6%
Valuation
P/E33.5833.5837.0436.64104.35
EV/EBITDA12.8112.8113.227.828.40
P/B7.647.648.604.073.76
Growth & Yield
Revenue Growth12.8%12.8%16.6%21.2%—
EPS Growth12.0%12.0%149.6%244.9%—
Dividend Yield1.8%1.8%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%

3Y implied EPS CAGR

43.1%

muy exigente

EPS terminal req.

$19.49

Spread vs growth

-31.1%

5Y implied EPS CAGR

28.8%

muy exigente

EPS terminal req.

$23.58

Spread vs growth

-16.9%

10Y implied EPS CAGR

19.0%

exigente

EPS terminal req.

$37.97

Spread vs growth

-7.1%

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -26.9%

Total return

-26.9%

Start / end P/E

51.9x → 33.0x

EPS bridge

5.94 → 6.65

Residual

-4.3%

EPS growth+12.0%
Multiple rerating-36.3%
Dividend+1.8%
Residual / FX / buybacks / cross-term-4.3%

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.